Developer of a non-absorbed oral therapeutic devices designed to target metabolic indications such as type 2 diabetes, obesity and NASH. The company is developing a drug which is orally administered, non-absorbed, gut restricted intestinal coating that mimics the therapeutic benefits of bariatric surgery on type 2 diabetes and simultaneously prevents stimulation of duodenal mucosa, enabling patients to avail an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia.